Literature DB >> 12582326

Human ocular mast cells.

Martin K Church1, James I McGill.   

Abstract

PURPOSE OF REVIEW: Seasonal allergic conjunctivitis is a common and clinically significant type I hypersensitivity response, in which the mast cell is considered to play a pivotal role in causing the signs and symptoms, including ocular itching, hyperaemia, lacrimation and chemosis. This review focuses on the biology of the human mast cell, particularly that of the human conjunctiva. RECENT
FINDINGS: The ocular mast cell not only releases histamine and eicosanoids into the extravascular environment when activated, but also synthesizes the cytokines IL-4 and TNF-alpha. The number of IL-4 messenger RNA-positive mast cells found in the conjunctival submucosa increases threefold in seasonal allergic conjunctivitis 'in season' compared with 'out of season', suggesting a role in disease. Treatment of the eye with 2% nedocromil sodium eye drops twice a day for 2 weeks reduced the tear concentrations of both histamine and prostaglandin D(2) by more than 70% at 30 min after challenge (both <0.05) illustrating an effective mast cell stabilizing effect in the conjunctiva.
SUMMARY: Mast cells are a heterogeneous family of cells that are pivotal in initiating the signs and symptoms of seasonal allergic conjunctivitis. The expression of cytokines also endows them with the ability to initiate the inflammatory cascade, resulting in eosinophil accumulation associated with vernal conjunctivitis. Drug modulation of mast cell activity, although reducing the acute symptoms of active disease, also reduces the cytokine stimulus for the development of chronic allergic inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12582326     DOI: 10.1097/00130832-200210000-00009

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  9 in total

1.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

2.  Modern approach to managing vernal keratoconjunctivitis.

Authors:  Sunil Kumar; Nitin Gupta; Anthony J Vivian
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

Review 3.  A review of the use of olopatadine in allergic conjunctivitis.

Authors:  James I McGill
Journal:  Int Ophthalmol       Date:  2004-05       Impact factor: 2.031

4.  Eyelash length for the diagnosis of atopic dermatitis and ichthyosis vulgaris in children-a case control study.

Authors:  Mehak Singh; Manoj Pawar
Journal:  Eur J Pediatr       Date:  2018-04-19       Impact factor: 3.183

Review 5.  An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.

Authors:  Susanna Esposito; Giulia Fior; Alessandro Mori; Silvia Osnaghi; Daniele Ghiglioni
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

Review 6.  [Therapeutic options in vernal keratoconjunctivitis].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

7.  Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%.

Authors:  Jack V Greiner; Kimberly Edwards-Swanson; Avner Ingerman
Journal:  Clin Ophthalmol       Date:  2011-01-13

8.  Elevated levels of prostaglandin E2 in the tears of patients with severe allergic conjunctivitis and primary cultured conjunctival cells are suppressed by ketotifen and dexamethasone.

Authors:  Ryutaro Yamanishi; Naoko Okada; Eisuke Shimizu; Hiroshi Fujishima
Journal:  BMJ Open Ophthalmol       Date:  2021-01-25

Review 9.  Autophagy in Extracellular Matrix and Wound Healing Modulation in the Cornea.

Authors:  Duraisamy Kempuraj; Rajiv R Mohan
Journal:  Biomedicines       Date:  2022-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.